JOHN KIRKWOOD to Ipilimumab
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Ipilimumab.
Connection Strength
4.537
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
Score: 0.735
-
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
Score: 0.670
-
Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 10 23; 6(1):112.
Score: 0.617
-
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C?melanoma is removed by surgery. Future Oncol. 2024 May; 20(15):959-968.
Score: 0.223
-
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024 01; 16(1):29-42.
Score: 0.219
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
Score: 0.203
-
Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653.
Score: 0.195
-
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020 06; 8(1).
Score: 0.173
-
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
Score: 0.155
-
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2018 02 01; 36(4):391-398.
Score: 0.144
-
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
Score: 0.143
-
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53.
Score: 0.117
-
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
Score: 0.111
-
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41.
Score: 0.096
-
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park). 2010 Dec; 24(14):1302, 1304.
Score: 0.089
-
Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
Score: 0.076
-
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024 May 01; 10(5):612-620.
Score: 0.057
-
Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
Score: 0.054
-
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):251-260.
Score: 0.052
-
Patient-reported tolerability of adjuvant ipilimumab (3 or 10?mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan; 32(1):183-196.
Score: 0.050
-
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
Score: 0.050
-
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 09 23; 385(13):1196-1206.
Score: 0.047
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
Score: 0.046
-
CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.
Score: 0.045
-
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358.
Score: 0.041
-
Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 2018 05; 19(5):e219.
Score: 0.037
-
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
Score: 0.036
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.031
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22.
Score: 0.026